CMS grants Medicare coverage for Personalis MRD test in lung cancer surveillance

The Centers for Medicare & Medicaid Services granted coverage for Personalis’ NeXT Personal molecular residual disease (MRD) assay for surveillance of stages I–III non‑small cell lung cancer. CMS cited clinical evidence from Personalis’ partnership with the TRACERx consortium and Nature Medicine data validating the test’s sensitivity to detect residual disease. NeXT Personal uses whole‑genome sequencing and noise‑suppression analytics to track hundreds to thousands of tumor‑specific mutations. Personalis called the decision a key step toward broader clinical access and said it will support commercialization and partnerships to expand surveillance in solid tumors.